Company intelligence / Profile preview

Nostos Genomics

Berlin, Berlin, Germanynostos-genomics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Nostos Genomics has developed and validated its AION platform with over 5,000 patient cases. The system analyzes all genetic variants in a person's DNA using explainable AI and functional genomics data, providing rapid (<2 minutes), accurate, and interpretable results for clinical diagnosis. It is already used by several genetic testing centers across Europe as part of an early access program. No drug or therapeutic trial results are applicable.

Therapeutic areas: Rare Diseases
Modalities: Non-pharmacological therapy (AI-driven diagnostic platform)Device (software platform for clinical labs)
Industry: Molecular Diagnostics

Partnerships

No major pharmaceutical or biotech partnerships disclosed; early access users include four European genetic testing centers including one of the largest in Europe.

Beyond the preview

Go deeper on Nostos Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nostos Genomics.

Explore the full profile